VIREXX ANNOUNCES SECOND QUARTER RESULTS

ViRexx Medical Corp., a company focused on immunotherapy treatments for cancer, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced its 2005 second quarter financial and operational results. "Development of ViRexx's clinical stage pipeline products continued to progress during the second quarter with enrollment increasing in each of the on-going clinical trials," said Marc Canton, president and chief operating officer of ViRexx. "The progress of the two Phase III OvaRex(R) MAb trials to treat ovarian cancer in consolidation as a monotherapy, together with a Phase II trial of OvaRex(R) MAb used in conjunction with chemotherapy to treat ovarian cancer in the front line setting, and the Phase I Occlusin(TM) 50 Injection, demonstrates the depth of our product pipeline."

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050815005147&newsLang=en)